Ventures L.P. 5Am Sells 10,494 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Ventures L.P. 5Am sold 10,494 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $7.00, for a total transaction of $73,458.00. Following the completion of the sale, the insider owned 2,836,098 shares in the company, valued at $19,852,686. The trade was a 0.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Entrada Therapeutics Trading Up 1.3%

Entrada Therapeutics stock opened at $7.04 on Wednesday. The company has a fifty day simple moving average of $6.87 and a 200-day simple moving average of $9.65. The stock has a market cap of $274.14 million, a P/E ratio of -1.78 and a beta of -0.26. Entrada Therapeutics, Inc. has a 12-month low of $5.02 and a 12-month high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The business had revenue of $0.90 million during the quarter, compared to analyst estimates of $2.32 million. As a group, sell-side analysts forecast that Entrada Therapeutics, Inc. will post -4.07 earnings per share for the current fiscal year.

Institutional Trading of Entrada Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in TRDA. Baker BROS. Advisors LP raised its stake in shares of Entrada Therapeutics by 4.3% during the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after buying an additional 206,911 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Entrada Therapeutics by 735.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 133,878 shares of the company’s stock worth $776,000 after buying an additional 117,844 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Entrada Therapeutics by 9.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock valued at $176,000 after purchasing an additional 1,560 shares in the last quarter. Great Lakes Advisors LLC purchased a new stake in Entrada Therapeutics in the 2nd quarter valued at approximately $283,000. Finally, BlackRock Inc. purchased a new position in Entrada Therapeutics during the second quarter worth $19,013,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Analyst Upgrades and Downgrades

TRDA has been the subject of several recent analyst reports. Roth Capital set a $10.00 price objective on shares of Entrada Therapeutics in a research report on Friday, May 8th. HC Wainwright downgraded shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Weiss Ratings cut Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. Finally, Guggenheim reduced their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a report on Monday, June 8th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $17.50.

Key Headlines Impacting Entrada Therapeutics

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: Institutional ownership remains high at approximately 86.4%. BlackRock opened a position worth about $19.0 million, while Millennium Management, Citadel Advisors and Qube Research increased their holdings. These purchases may provide some underlying demand for TRDA shares.
• Positive Sentiment: Analyst coverage remains mixed but includes three Buy ratings. The average price target is reported at $17.50, well above recent trading levels, although HC Wainwright downgraded the stock to Neutral and Guggenheim lowered its target to $17.00. Entrada Therapeutics analyst and stock information
• Neutral Sentiment: Reported short interest was zero shares, with a zero-day days-to-cover ratio. Because the data also shows an “NaN” change from the prior period, it offers little reliable insight into current short-selling pressure.
• Negative Sentiment: Major shareholder Ventures V. L.P. 5Am sold a combined 62,811 shares on August 6 and 7 for approximately $431,829, reducing its position by about 2.2%. The shareholder still owns more than 2.7 million shares, so the sales represent a modest reduction rather than a full exit. SEC filing on Ventures V. L.P. 5Am share sales
• Negative Sentiment: Director Kush Parmar sold 155,255 shares across three transactions from August 6 through August 10 for roughly $1.08 million, cutting his holdings by approximately 5.5%. Repeated insider selling can weigh on sentiment, even though he continues to hold a substantial stake. SEC filing on Kush Parmar share sales
• Negative Sentiment: Entrada’s latest quarterly results missed expectations: adjusted loss per share was $1.01 versus an expected $0.97 loss, while revenue of $0.90 million fell short of the $2.32 million consensus. The clinical-stage biotechnology company is expected to remain unprofitable, with analysts forecasting a full-year loss of approximately $4.07 per share.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.